

References

1. Bloom-Feshbach K, Alonso WJ, Charu V, et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. *PLoS One*. 2013;8(2):e54445. ([HERE](#))
2. CDC. COVID Data Tracker. (Accessed 7/23/24) ([HERE](#))
3. CDC. COVID-19 Wastewater Surveillance. (Accessed 7/23/24) ([HERE](#))
4. CDC. Emergency Use Instructions (EUI) Fact Sheet for Healthcare Providers: Oseltamivir for Treatment or Post-Exposure Prophylaxis of Novel Influenza A. (Accessed 7/24/2024) ([HERE](#))
5. CDC. Summary of Variant Surveillance. (accessed 7/23/24) ([HERE](#))
6. CDC. Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2. ([HERE](#))
7. Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. *Ann Med*. 2022 Dec;54(1):524-540. ([HERE](#))
8. GOV.UK. COVID-19 – 7/18/2024 (Accessed 7/23/24) ([HERE](#))
9. Kumar P, Jayan J, Sharma RK, et al. The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape. *QJM*. 2024 Jun 12:hcae102. ([HERE](#))
10. Li P, Faraone JN, Hsu CC, et al. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. *bioRxiv* [Preprint]. 2024 May 21:2024.05.20.595020. ([HERE](#))
11. Li P, Faraone JN, Hsu CC, et al. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. *bioRxiv* [Preprint]. 2024 May 21:2024.05.20.595020. ([HERE](#))
12. Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. *MMWR Morb Mortal Wkly Rep*. 2024 Feb 1;73(4):77-83. ([HERE](#))
13. UK Health Security Agency. Should we be worried about the new COVID-19 variant? 5/13/2024 (Accessed 7/23/24) ([HERE](#))
14. Wang L, Møhlenberg M, Wang P, et al. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. *Cytokine Growth Factor Rev*. 2023 Apr;70:13-25. ([HERE](#))